A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome
Latest Information Update: 28 Mar 2022
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Adult respiratory distress syndrome
- Focus Registrational; Therapeutic Use
- Acronyms INTEREST
- Sponsors Faron Pharmaceuticals
- 26 Mar 2022 This trial is completed in Belgium (End Date: 23 May 2018), according to European Clinical Trials Database record.
- 20 May 2020 According to a Faron Pharmaceuticals media release, results of this study have been published in Intensive Care Medicine
- 17 Feb 2020 Primary endpoint (Efficacy Endpoint: Days free of mechanical ventilation) has not been met published in the JAMA: the Journal of the American Medical Association